Andrew Huberman interviews University of Utah biochemist and HHMI investigator Jared Rutter on how mitochondria shape metabolism, disease and cellular decision-making. Rutter argues that “metabolism” at the organism level is the sum of many different cellular metabolisms, each tuned to a cell’s job—such as continuous ATP production in heart muscle versus rapid biosynthesis in gut stem cells.
The discussion centres on pyruvate as a metabolic pivot: cells can import it into mitochondria for oxidation and ATP generation, or divert it into pathways that support biomass production and lactate. Rutter describes work identifying MPC1 and MPC2 as the mitochondrial pyruvate carrier, a function inferred for decades before the proteins were found, and outlines how genetic loss of MPC has cell-type-dependent consequences. He says global loss is embryonically lethal, while heart-specific loss leads to a dilated, enlarged heart and eventual failure, which he interprets as maladaptive rerouting of carbon into growth rather than an ATP deficit.
On cancer, Rutter reframes the Warburg effect as a shift in resource allocation rather than “broken” mitochondria, arguing tumour mitochondria can be highly functional for biosynthesis. He also predicts oncology will increasingly rely on personalised combinations of targeted drugs to reduce resistance. The episode closes with discussion of reactive oxygen species as a hypothesised consequence of “overpowered” mitochondria and the challenges of measuring metabolism non-invasively at cellular resolution in humans.
Dr Jared Rutter says the mitochondrial pyruvate carrier (MPC) transports pyruvate across the mitochondrial membrane for oxidation. He recalls that biochemists inferred such a carrier for 60–70 years, but the responsible proteins were only identified more recently through lab work including his group’s.
Read this moment →